[ad_1]
In a statement, Moderna reveals that the final results of the Covid-19 vaccine tests demonstrate a 94.1 percent effective, with an efficiency that reaches 100 percent when it comes to severe cases.
The tests in question included 196 participants with confirmed cases of Covid-19, including 30 severe cases.
The pharmaceutical company adds that “the efficacy of the vaccine was consistent in terms of age, race, ethnicity and gender.”
The 196 cases included older adults (over 65 years) and “42 participants who identified themselves as from different communities.”
He adds that the the vaccine “remains generally well tolerated, with no record of cases with serious effects identified to date “.
Emergency authorization
With these results, Moderna will still apply today for emergency clearance from the Food and Drug Administration (FDA) in the US.. The US pharmaceutical company expects the results of these tests to be considered at the Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which takes place on December 17.
Likewise, today an emergency authorization will continue to be requested from the European Medicines Agency (EMA). In the coming days, Moderna intends to proceed with the registration procedure at the World Health Organization (WHO).
Despite rapid advances, this vaccine is expected to reach the North American market first. Moderna received $ 2.48 billion in federal funding from the United States as part of the Trump Administration’s Operation Warp Spped.
This pharmaceutical company already has contracts signed in various parts of the world for the supply of the vaccine, but The United States alone should have 20 million doses available by the end of 2020.
In August, the United States purchased a total of 100 million doses, with the option to purchase an additional 500 million. Moderna guarantees that it will manufacture between 500 million and 1 billion doses globally during the next year.
This is the third vaccine to pass the last phase of testing after the results revealed by Pfizer and AstaZeneca / Oxford University. It is known by now that the Pfizer vaccine needs very low temperatures to be stored (in the range of -70 to -80ºC), while the Moderna vaccine tolerates less demanding temperatures, but has a very high cost, limiting its universality.
The British vaccine at the University of Oxford is less effective (70 percent) but is more affordable in terms of price and does not require such low temperatures.
